AUTHOR=Wang Anzhu , Zhao Wei , Yan Kaituo , Huang Pingping , Zhang Hongwei , Ma Xiaochang 

TITLE=Preclinical Evidence of Paeoniflorin Effectiveness for the Management of Cerebral Ischemia/Reperfusion Injury: A Systematic Review and Meta-Analysis

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 13 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.827770

DOI=10.3389/fphar.2022.827770

ISSN=1663-9812

ABSTRACT=Background: Vessel recanalization is the main treatment for ischemic stroke; however, not all patients benefit from it. This lack of treatment benefit is related to the accompanying ischemia-reperfusion (I/R) injury. Therefore, neuroprotective therapy for I/R Injury needs to be further studied. Paeonia lactiflora Pall. is a commonly used for ischemic stroke management in traditional Chinese medicine; its main active ingredient is paeoniflorin (PF).
Purpose: We aimed to determine the PF’s effects and the underlying mechanisms in instances of cerebral I/R injury. 
Study Design: We searched seven databases from their inception to July 2021.
Methods: SYRCLE's risk of bias tool was used to assess methodological quality, and STATA 12.0 software was used for meta-analysis.
Results: Thirteen studies including 282 animals overall were selected. The meta-analyses showed compared to control treatment, PF significantly reduced neurological severity scores, cerebral infarction size, and brain water content (P = 0.000). In the PF treatment groups, the apoptosis cells and levels of inflammatory factors (IL-1β, TNF-α, and IL-6) decreased compared to those in the control groups (P = 0.000).
Conclusions: Our results suggest that PF is a promising therapeutic for cerebral I/R injury management. However, to evaluate the effects and safety of PF in a more accurate manner, additional preclinical studies are necessary.